PerkinElmer Announces New Innovations to Strengthen Drug Discovery Product Portfolio
ST. LOUIS-- (BUSINESS WIRE)--April 4, 2008--PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, today announced the release of eight new AlphaLISA™ immunoassay kits in conjunction with the Society for Biomolecular Sciences' (SBS) 14th Annual Conference and Exhibition. These latest innovations include research reagents and assays for investigating HIV, cancer, central nervous system disorders, cardiovascular disorders, and diabetes(a).
AlphaLISA™ is a line of highly sensitive "No-Wash" immunoassay reagents offering a wide dynamic range and easy automation for analysis of biomarkers and other analytes. The technology allows researchers to replace multi-step, cumbersome ELISAs with a high throughput screening (HTS) platform, significantly reducing the time, labor and materials necessary for processing complex samples.
"At PerkinElmer, we are committed to providing our customers with the technologies and innovations they need to further push the boundaries of research taking place in today's laboratories," said Richard Eglen, Ph.D., president, Bio-discovery, PerkinElmer, Inc. "The release of these eight new AlphaLISA assay kits will not only provide researchers with the latest tools they need to produce more accurate results across a wider range of diseases, but also expand and strengthen our line of drug discovery products in new and existing markets."
AlphaLISA™ is a proprietary bead-based homogeneous assay technology for the detection of analytes in complex samples such as serum. In addition, the proximity of the two beads allows the detection of very large analytes such as full length endogenous proteins and biological complexes. The beads are extremely small in comparison to other bead technologies and can be dispensed very easily. AlphaLISA™'s unique, No-Wash technology eliminates tedious ELISA washing and consecutive incubation wait times, and offers greater dynamic range and sensitivity, while enabling miniaturization and ease of automation.
(a)AlphaLISA™ assay kits are intended for research use only and are not for use in diagnostic procedures.
Factors Affecting Future Performance
This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow, revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers' demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) our failure to comply with health care industry regulations; (11) economic, political and other risks associated with foreign operations; (12) our ability to retain key personnel; (13) restrictions in our credit agreements; (14) our ability to realize the full value of our intangible assets; and (15) other factors which we describe under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.8 billion in 2007, has 9,100 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.
CONTACT:
PerkinElmer, Inc.
Investor Relations:
Michael A. Lawless, 781-663-5659
or
Media Contact:
Stephanie Wasco, 781-663-5701
SOURCE: PerkinElmer, Inc.